Funding Received
$57.9 Million in 1 Round from 3 Investors
Most Recent Funding
$57.9 Million Series E on November 18, 2013
Headquarters:
Mainz
Description:
Ganymed Pharmaceuticals is a biopharmaceutical developing therapeutic drugs designed to kill tumor cells without harming healthy tissues.
Categories:
Biotechnology
Website:
http://ganymed-pharmaceuticals.de

Company Details

Update
Founded:
2001
Contact:
Employees:
2 in CrunchBase

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

Current Team (2)

Update

Funding Rounds (1) - $57.9M

Update

Offices/Locations (1)

Update
  • Office

    Freiligrathstrasse 12

    Mainz, 55131

    DEU

Images (1)

Update
  • 1c9074db241d4984696a093ce91cd737